TrialBMC cancer2015
Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.
Seung Tae Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this paperpooled ittrialcites it